智通财经APP讯,佰金生命科学(01466)发布公告,于2025年9月29日,公司收到债券持有人发出的转换通知,内容有关按换股价每股换股股份0.2628港元行使本金额为3150万港元的可换股债券所附带换股权。因此,1.199亿股换股股份(相当于公司现有已发行股本约15.52%及公司经发行换股股份扩大后的已发行股本约13.43%)已于2025年10月8日配发及发行予债券持有人。
智通财经APP讯,佰金生命科学(01466)发布公告,于2025年9月29日,公司收到债券持有人发出的转换通知,内容有关按换股价每股换股股份0.2628港元行使本金额为3150万港元的可换股债券所附带换股权。因此,1.199亿股换股股份(相当于公司现有已发行股本约15.52%及公司经发行换股股份扩大后的已发行股本约13.43%)已于2025年10月8日配发及发行予债券持有人。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.